Soleno Therapeutics faces securities class action over DCCR safety disclosures

Reuters03-16

<a href="https://laohu8.com/S/SLNO">Soleno Therapeutics</a> faces securities class action over DCCR safety disclosures

Investors filed a securities class action against Soleno and certain senior executives in the U.S. District Court for the Northern District of California, captioned City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, No. 26-cv-01979. The suit covers purchases of Soleno common stock from March 26, 2025 to November 4, 2025 and alleges violations of the Securities Exchange Act of 1934. Plaintiffs allege the company downplayed or concealed safety concerns tied to DCCR, including excess fluid retention, affecting the drug’s risk profile and commercial viability. The filing cites a Scorpion Capital report followed by a stock decline of nearly 12% over two trading days. It also cites a disclosure of a patient death after taking DCCR, followed by an approximately 19% stock decline over two trading days, and later results citing launch disruption followed by an approximately 27% decline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603160945PR_NEWS_USPR_____LA09931) on March 16, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619002466?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 21:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619002466","market":"nz","top_or_hot":-1,"title":"Soleno Therapeutics faces securities class action over DCCR safety disclosures","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> faces securities class action over DCCR safety disclosures\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Investors filed a securities class action against Soleno and certain senior executives in the U.S. District Court for the Northern District of California, captioned City of Pontiac Police and Fire Retirement System v. Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, No. 26-cv-01979. The suit covers purchases of Soleno common stock from March 26, 2025 to November 4, 2025 and alleges violations of the Securities Exchange Act of 1934. Plaintiffs allege the company downplayed or concealed safety concerns tied to DCCR, including excess fluid retention, affecting the drug’s risk profile and commercial viability. The filing cites a Scorpion Capital report followed by a stock decline of nearly 12% over two trading days. It also cites a disclosure of a patient death after taking DCCR, followed by an approximately 19% stock decline over two trading days, and later results citing launch disruption followed by an approximately 27% decline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603160945PR_NEWS_USPR_____LA09931) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Soleno Therapeutics faces securities class action over DCCR safety disclosures</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSoleno Therapeutics faces securities class action over DCCR safety disclosures\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-16 21:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/SLNO\">Soleno Therapeutics</a> faces securities class action over DCCR safety disclosures\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Investors filed a securities class action against Soleno and certain senior executives in the U.S. District Court for the Northern District of California, captioned City of Pontiac Police and Fire Retirement System v. Soleno <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, No. 26-cv-01979. The suit covers purchases of Soleno common stock from March 26, 2025 to November 4, 2025 and alleges violations of the Securities Exchange Act of 1934. Plaintiffs allege the company downplayed or concealed safety concerns tied to DCCR, including excess fluid retention, affecting the drug’s risk profile and commercial viability. The filing cites a Scorpion Capital report followed by a stock decline of nearly 12% over two trading days. It also cites a disclosure of a patient death after taking DCCR, followed by an approximately 19% stock decline over two trading days, and later results citing launch disruption followed by an approximately 27% decline.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603160945PR_NEWS_USPR_____LA09931) on March 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL9WFxLr:1","article_id":"2619002466","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619002466","pubTimestamp":1773668725,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Investors filed a securities class action against Soleno and certain senior executives in the U.S. District Court for the Northern District of California, captioned City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, No. 26-cv-01979. The suit covers purchases of Soleno common stock from March 26, 2025 to November 4, 2025 and alleges violations of the Securities Exchange Act of 1934. Plaintiffs allege the company downplayed or concealed safety concerns tied to DCCR, including excess fluid retention, affecting the drug’s risk profile and commercial viability. The filing cites a Scorpion Capital report followed by a stock decline of nearly 12% over two trading days. It also cites a disclosure of a patient death after taking DCCR, followed by an approximately 19% stock decline over two trading days, and later results citing launch disruption followed by an approximately 27% decline.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SLNO":"Soleno Therapeutics"},"translate_title":"Soleno Therapeutics因DCCR安全披露面临证券集体诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLNO":0.9},"content_text":"Soleno Therapeutics faces securities class action over DCCR safety disclosures\n    \n\n        Investors filed a securities class action against Soleno and certain senior executives in the U.S. District Court for the Northern District of California, captioned City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, No. 26-cv-01979. The suit covers purchases of Soleno common stock from March 26, 2025 to November 4, 2025 and alleges violations of the Securities Exchange Act of 1934. Plaintiffs allege the company downplayed or concealed safety concerns tied to DCCR, including excess fluid retention, affecting the drug’s risk profile and commercial viability. The filing cites a Scorpion Capital report followed by a stock decline of nearly 12% over two trading days. It also cites a disclosure of a patient death after taking DCCR, followed by an approximately 19% stock decline over two trading days, and later results citing launch disruption followed by an approximately 27% decline.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soleno Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202603160945PR_NEWS_USPR_____LA09931) on March 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding,policyRegulatory,event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619002466","isCrawlerRequest":true}